Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program

Sheldon W Tobe, Luc Poirier, Guy Tremblay, Patrice Lindsay, Debra Reid, Norman RC Campbell, Nadia Khan, Robert R Quinn, Doreen Rabi, on behalf of the Canadian Hypertension Education Program

Sheldon W. Tobe, MD, is chair of the Canadian Hypertension Education Program and associate professor in the Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario. Luc Poirier, MSc, is chair of the Recommendations Task Force for the Canadian Hypertension Education Program and a senior pharmacist in the Hypertension Unit and Pharmacy Department, Centre hospitalier universitaire de Québec, Université Laval, Sainte-Foy, Québec. Guy Tremblay, MD, is professor of medicine, Centre hospitalier universitaire de Québec, Hôpital du Saint-Sacrement, and cardiovascular consultant, Direction de la santé publique de la Capitale-Nationale, Sainte-Foy, Québec. Patrice Lindsay, PhD, is director of performance and standards, Canadian Stroke Network, an adjunct professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, and a member of the Canadian Task Force on Preventive Health Care, Toronto, Ontario. Debra Reid, PhD, is a registered dietitian and national manager of the Strengthening the Forces health promotion program in the Department of National Defence, Ottawa, Ontario. Norman R.C. Campbell, MD, is a professor of medicine, of community health sciences and of physiology and pharmacology at the University of Calgary, a member of the Libin Cardiovascular Institute of Alberta, and CIHR Canada Chair in Hypertension Prevention and Control in Calgary, Alberta. Nadia Khan, MD, is an associate professor of medicine and clinician scientist at the Centre for Health Evaluation and Outcomes Sciences, Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia. Robert R. Quinn, MD, PhD, is an adjunct assistant professor in the Division of Nephrology, University of Calgary, Calgary, Alberta. Doreen Rabi is an assistant professor in the Departments of Medicine, Community Health and Cardiovascular Sciences at the University of Calgary, Calgary, Alberta.

Competing interests: Sheldon Tobe has received unrestricted grant support from Servier and has participated in contract research with Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck, Novartis, Pfizer, Sanofi-aventis and Takeda. Luc Poirier has served on the advisory boards of Novartis Canada and Janssen Canada and has participated in research protocols with Takeda, Novartis and Merck. Norman Campbell received travel support in 2010 from Boehringer Ingelheim to attend meetings on hypertension.

Funding: The Canadian Hypertension Education Program’s consensus conference and guidelines were funded by Hypertension Canada, which receives funds from multiple industry sources and the Public Health Agency of Canada.

Correspondence: Sheldon W. Tobe, Division of Nephrology, Faculty of Medicine, Sunnybrook Health Sciences Centre, A240, 2075 Bayview Avenue, Toronto, ON M4N 3M5; sheldon.tobe@sunnybrook.ca

For 13 years, the Canadian Hypertension Education Program has been producing annually updated recommendations and clinical practice guidelines related to the detection, treatment and control of hypertension. In this article we provide background information on the updates generated at this year’s consensus conference, and we summarize the key new recommendations (Box 1). The 2012 recommendations have prevention as their theme. The full recommendations are available online at www.hypertension.ca.

CLINICAL VIGNETTE

You see a 68-year-old retired man in your office for follow-up of his blood pressure (BP). His past medical
history includes myocardial infarction with systolic dysfunction, dyslipidemia and chronic kidney disease (estimated glomerular filtration rate [eGFR] 48 mL/min). He is otherwise well, he does not have diabetes, and he can walk 4 blocks without any limitations imposed by symptoms. His current medications include an angiotensin converting enzyme (ACE) inhibitor, a beta blocker, acetylsalicylic acid and a statin. On previous examination his BP was 154/92 mm Hg, and today it is 150/90 mm Hg. He is surprised by these BP readings, as his BP was considerably lower when he checked it at the supermarket. He asks whether his readings are elevated because he is nervous and is worried that he will need more medications, given that he is already taking “too many pills.”

You discuss with him the white-coat effect on blood pressure and the importance of achieving BP targets. You provide him with the Measure Blood Pressure At Home tool from the Hypertension Canada website (www.hypertension.ca) and ask him to measure his BP at home using his wife's home BP monitor; this device has been endorsed by Hypertension Canada. You arrange for him to return in 2 weeks for additional follow-up.

MANAGING HYPERTENSION BY THE NUMBERS
The prevalence of hypertension in Canada is predicted to reach 7,500,000 in 2012/2013; over 1,000 people are diagnosed with hypertension daily in this country. These numbers are largely driven by the aging of the baby-boom generation and their sedentary lifestyle and unhealthy eating habits (in particular, their consumption of excess sodium). Since the initiation of the CHEP in 1999, the awareness, treatment and control of hypertension have greatly improved. The percentage of Canadians who report that they are aware they have hypertension but are not receiving treatment has fallen dramatically, whereas the percentage of Canadians with hypertension whose condition is treated and controlled has risen from 13% in 1992 to 66% in recent surveys. In association with the improvements in BP control, mortality rates for stroke, heart failure and heart attack have fallen faster in Canada in the past 10 years than in the previous decade. In the United States, it is estimated that health care costs related to newly diagnosed cases of hypertension will be $130.4 billion more in 2030 than they were in 2010, under-scoring the importance of the theme for CHEP’s 2012 clinical practice recommendations: prevention.

THE IMPORTANCE OF PREVENTION
Despite continuous advancements in reducing the prevalence of cardiovascular diseases, these diseases remain a major cause of disability and premature death and contribute substantially to the escalation of health care costs in Canada. Modifications in individuals' exposures to behavioural, environmental and societal risk factors can prevent or delay the onset of chronic disease and resulting disabilities and represent a feasible and practical target for change at both clinical and population levels. High BP is the most common and important modifiable risk factor for a range of chronic diseases, including coronary artery disease, stroke, congestive heart failure, chronic kidney disease, peripheral arterial disease and dementia.

The majority of Canadians will develop hypertension if they live an average lifespan. Therefore, even modest changes in BP have significant potential to reduce the current burden of chronic disease.

More emphasis on maintaining a healthy lifestyle (eating a diet high in fresh fruit and vegetables, with low-fat dairy products that are low in saturated fats and sodium [DASH diet], exercising regularly, attaining and maintaining a healthy body weight and abdominal girth, engaging in low-risk alcohol consumption and living in a smoke-free environment) and on preventing or delaying chronic diseases will improve the quality of life of Canadians while reducing the impact these conditions have on individuals, families, communities, the health care system and society. A supportive environment (e.g., a food supply with limited processed foods that contain saturated and trans fats, simple sugars and added sodium and built communities that encourage regular physical activity) is critical to the implementation of lifestyle recommendations. Reducing sodium additives in foods is an important environmental policy, and readers are encouraged to visit www.sodium101.ca to see how they can become more engaged.

2012 UPDATE OF CHEP’S RECOMMENDATIONS

Home monitoring

Recommendation. If the average home BP is less than 135/85 mm Hg, it is advisable to either repeat home monitoring to confirm that the home BP is less than 135/85 mm Hg or perform 24-hour ambulatory BP monitoring (ABPM) to confirm that the mean 24-hour ABPM is less than 130/80 mm Hg and the mean awake ABPM is less than 135/85 mm Hg, before diagnosing white-coat hypertension.

BP varies across individuals, making its assessment challenging. New information on BP measurement has expanded the role of home BP monitoring in addition to ABPM to aid the diagnosis of white-coat and masked
Clinical vignette revisited. The patient returns after 2 weeks with BP readings from home averaging 148/92 mm Hg. The CHEP recommendation for systolic pressure measured at home is less than 135 mm Hg, equivalent to a standardized office measurement of 140 mm Hg systolic. With a coefficient of variation of 5.5%, the standard deviation for a systolic pressure of 148 mm Hg is 8.1 mm Hg. Eighty percent of measurements will be between 1.28 standard deviations (137–158 mm Hg), and thus you can now safely rule out white-coat hypertension.

BP target for patients with non-diabetic chronic kidney disease

Recommendation. For patients with non-diabetic chronic kidney disease, the target BP is less than 140/90 mm Hg.

CHEP had previously recommended that individuals with non-diabetic chronic kidney disease be treated to a BP target of less than 130/80 mm Hg, in keeping with a meta-analysis demonstrating that achieving systolic pressures below 120 mm Hg was associated with better outcomes in patients with proteinuria. However, our critical reappraisal of the literature did not support treating this patient population to a more stringent BP target than that for the general population, even in the setting of significant proteinuria. As a consequence, this recommendation has been removed, and CHEP now recommends that patients with non-diabetic chronic kidney disease be treated to the same BP target as the general population (140/90 mm Hg), on the basis of current evidence. A summary of the relevant literature follows.

Modification of Diet in Renal Disease study. In the Modification of Diet in Renal Disease (MDRD) study of patients with chronic kidney disease and a low glomerular filtration rate (GFR), there was no difference between the groups with usual BP target (mean arterial pressure [MAP] 107 mm Hg; BP approximately 140/90 mm Hg) and low BP target (MAP 92 mm Hg; BP approximately 125/75 mm Hg) with respect to the slope of decline in GFR or secondary outcomes including kidney failure, death, a composite of kidney failure or death, and cardiovascular events. A long-term follow-up of the MDRD cohort demonstrated that individuals who had originally been randomly assigned to the group with the low BP target had a lower hazard of kidney failure. However, this difference was not apparent during the trial, and there was no information about the therapy these patients received, the BP targets or the BP achieved in each group after the trial was completed.

In the original MDRD report, subgroup analyses also suggested that there was a significant interaction between baseline proteinuria and BP target (p = 0.02), and a re-analysis of the MDRD data showed that the rate of GFR decline appeared to increase above a MAP
of 98 mm Hg in patients with between 0.25 g and 3 g of proteinuria per day. It is important to note that this was a post-hoc subgroup analysis and that randomization was not stratified on the basis of level of proteinuria. In addition, the proteinuria categories were not prespecified, and there were no *a priori* power calculations done for the subgroups. The level of statistical significance was not adjusted for multiple testing, and baseline patient characteristics were not presented according to subgroup. Finally, the use of ACE inhibitors was higher in the patients assigned to the low BP target, and this may very well have influenced outcomes. In summary, although there was a suggestion that patients with higher degrees of proteinuria at baseline may benefit from a lower BP target, these results should have been interpreted as hypothesis generating, but they played a role in the initial adoption of a BP target of less than 125/75 mm Hg for patients with 1 g or more of proteinuria per day.

**African American Study of Kidney Disease and Hypertension trial.** The African American Study of Kidney Disease and Hypertension (AASK) study had a $2 \times 3$ factorial design with 2 different BP levels and 3 classes of antihypertensive medications (ACE inhibitor, calcium-channel blocker and beta blocker). The participants were African Americans with non-diabetic kidney disease. In the BP-lowering component of the AASK trial, there was no significant difference in renal outcomes (the chronic slope or the overall rate of decline in GFR per year) over the study period between individuals randomly assigned to the usual-BP goal (MAP 102–107 mm Hg) and those assigned to a low-BP goal (MAP 92 mm Hg). Patients assigned to the low-BP group experienced a 17% reduction in proteinuria, whereas those in the usual-BP goal experienced a 7% increase. There was no difference between the groups in the risk of kidney failure, the composite of kidney failure or death, the composite of a GFR event or death, or the combined end point of GFR event, kidney failure or death. There was also no difference in cardiovascular mortality or non-fatal cardiovascular events.

In the AASK trial there was also an interaction between baseline proteinuria (stratified as less than or equal to 300 mg per day or greater than 300 mg per day) and BP group assignment. This interaction was interpreted to mean that patients with higher levels of proteinuria might benefit from a more intensive BP target. However, the interaction appeared to be driven by the fact that patients with low levels of proteinuria who were randomly assigned to the low-BP group had worse outcomes than the usual-BP group. When the authors stratified the analysis according to level of proteinuria, the BP comparison “was not significantly different within either the lower (baseline urinary protein to creatinine ratio $\leq 0.22$) or higher (baseline urinary protein to creatinine ratio $> 0.22$) proteinuria strata” for the secondary clinical composite outcome (doubling of serum creatinine level, kidney failure or death).

A subsequent re-analysis of the AASK trial, which included a cohort follow-up period, used the secondary clinical composite outcome from the initial report as the primary outcome of interest. In this analysis, a significant reduction (26%) in the relative hazard of the outcome was reported ($p = 0.04$) in patients randomly assigned to the low-BP target who had more than 300 mg of proteinuria per day (protein to creatinine ratio greater than 0.22). The explanation for the discrepant findings in the 2 reports is unclear. In the original study, a mixed-effects model was used to model the relationship between BP target and outcomes. It appears that the re-analysis adjusted for the same fixed effects, but no mention was made of random effects being incorporated into the statistical models. Finally, although this re-analysis was focused on renal outcomes, no mention of the primary renal outcome in the original trial was made. Regardless, this analysis represented a subgroup analysis of a secondary end point in the original trial. Similar to the re-analysis of the MDRD data, this was a post-hoc subgroup analysis and randomization was not stratified on the basis of level of proteinuria. The proteinuria categories were not specified before the start of the trial but rather were set before the start of the analysis. There were no *a priori* power calculations for the subgroups, and the level of statistical significance was not adjusted for multiple testing. Although there was a suggestion that patients with more than 300 mg of proteinuria per day at baseline may derive benefit from a lower BP target and that those with less proteinuria may experience worse outcomes, these results should again be interpreted with caution.

**Blood Pressure Control for Renoprotection in Patients with Chronic Renal Disease trial.** The Blood Pressure Control for Renoprotection in Patients with Chronic Renal Disease (REIN-2) trial is the only randomized trial to specifically look at the impact of BP targets on outcomes in individuals with proteinuric, non-diabetic renal disease. Investigators randomly
assigned patients with more than 1 g of proteinuria per day to conventional BP control (target diastolic BP < 90 mm Hg) or intensified BP control (target BP < 130/80 mm Hg). All patients were treated with ramipril, and the group with intensive BP control received 5–10 mg of felodipine per day to achieve targets. Additional agents were used as needed. The study was stopped owing to futility after a median of 19 months of follow-up. There was no difference in the adjusted hazard of reaching kidney failure between the conventional and intensive control groups (hazard ratio 1.00, 95% confidence interval 0.61–1.64).

This study has been criticized because of the use of a dihydropyridine calcium-channel blocker in the group with the intensive BP control, the small difference in BP between groups and the limited amount of follow-up. In addition, because of the sample size there was limited power to rule out a clinically important difference. However, the REIN-2 trial was the only randomized study to specifically look at the impact of BP targets on outcomes in individuals with proteinuric, non-diabetic renal disease.

Overall, the evidence to support a more stringent BP target in patients with chronic kidney disease is of low quality, and the randomized trials conducted to date suggest that there is no benefit to reducing BP to targets less than 140/90 mm Hg. Despite observational evidence suggesting that more intensive BP control may be beneficial in individuals with more than 300 mg or more than 1 g per day of proteinuria, the lone randomized trial examining this issue had negative results. Although an important benefit cannot be ruled out, the current evidence base does not support a more intensive BP target in this group.

Various guidelines have recommended a target BP of less than 130/80 mm Hg for patients with chronic kidney disease without diabetes. In recent years there has been a retrenchment from this lower target. The National Institute for Health and Clinical Excellence guidelines for chronic kidney disease maintained the target of less than 130/80 mm Hg but only when the production of urine protein was 1 g per day or greater; otherwise, the target was less than 140/90 mm Hg.

**BP target for patients with diabetes mellitus**

**Recommendation.** Patients with diabetes mellitus should be treated to attain BP of less than 130/80 mm Hg.

This recommendation for patients with diabetes, including those with chronic kidney disease, remains unchanged. For people with diabetes and hypertension, the diastolic target of 80 mm Hg was established in response to the findings of the Hypertension Optimal Treatment trial, but the systolic target continues to be a topic of discussion. The results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial were reported in 2010 and were reviewed and debated again at the 2012 CHEP consensus conference. This trial compared the outcomes in an intensive-treatment arm (with a systolic target of less than 120 mm Hg) with the outcomes in a standard-treatment arm (with a target of less than 140 mm Hg). Overall the study was neutral for the main outcome measure (the risk of major cardiovascular events), which argues in favour of moving the systolic target to less than 140 mm Hg. However, the study did not test a target of less than 130 mm Hg, which is the current recommendation for people with diabetes. Furthermore, the study had been powered for an event rate double the 2.00% found in the standard-treatment arm, so the study may have been underpowered. This argues in favour of lowering the systolic recommendation at the current target of less than 130 mm Hg. Patients in the intensive-treatment arm had a significantly lower risk of stroke (47% less) associated with more hypotension, bradycardia and hyperkalemia; this finding argues for a target BP of less than 120 mm Hg if the goal is to prevent stroke.

Overall, the ACCORD trial raised questions about the relative benefits and risks of achieving lower systolic BP targets. It may be that lowering BP in patients with diabetes has more complex effects than previously thought and the target for the systolic BP may depend on what end point we are trying to prevent. Furthermore, intensive BP reduction in patients with hypertension and diabetes may result in a trade-off between stroke reduction and an increased risk of drug-related adverse effects.

**Clinical vignette revisited.** The patient’s BP is currently still above target. You consider which medications to add, given his history of heart failure and previous myocardial infarction.

**Treatment of patients with hypertension and systolic dysfunction**

**Recommendation.** Aldosterone antagonists (mineralocorticoid-receptor antagonists) may be added for patients with hypertension and systolic dysfunction.

As part of an ongoing effort to harmonize related recommendations between guidelines groups, CHEP and the Canadian heart failure guidelines group developed
a harmonized recommendation for managing patients with systolic heart failure and hypertension. The RALES, EPHESUS and EMPHASIS-HF studies all demonstrated reductions in the rates of death and hospital admission for heart failure in patients with systolic dysfunction who were receiving mineralocorticoid-receptor antagonists. Over 60% of the patients in these studies had a diagnosis of hypertension, and BP was controlled in most patients at study entry. On the basis of the results of these studies, an aldosterone antagonist is recommended for patients with a history of hypertension and recent admission to hospital for a cardiovascular condition, acute myocardial infarction, elevated B-type natriuretic peptide or N-terminal pro B-type natriuretic peptide levels, or New York Heart Association class II to IV symptoms. Because of the risk of hyperkalemia, when an aldosterone antagonist is added to inhibitors of the renin–angiotensin–aldosterone system, appropriate monitoring for hyperkalemia is recommended. The harmonized recommendation does not specify the period within which potassium should be measured after this therapy is started; it depends on the risk for an individual patient (e.g., potassium should be measured within 1 week for individuals at very high risk). The Canadian heart failure guidelines recommend that spironolactone not be used in patients with an eGFR of less than 30 mL·min⁻¹·1.73 m⁻² or a serum potassium level of more than 5.0 mmol/L. The incidence of hyperkalemia in the EPHESUS and EMPHASIS-HF studies was significantly higher in patients treated with eplerenone than in patients who received a placebo (Table 1).

The adverse event rate for gynecomastia was 0.7% for patients receiving eplerenone in the EMPHASIS-HF trial, which was not significantly different from that in the placebo arm in either study. In the RALES study, gynecomastia was reported in 10% of men receiving an average dose of 26 mg spironolactone per day, whereas it was 1% in the placebo arm.

# RESOLUTION OF CLINICAL VIGNETTE

After discussion with the patient, you start him on spironolactone. You arrange electrolyte testing for potassium for the following week and counsel him about the potential for gynecomastia. His potassium level is 4.6 mmol/L a week later, and his follow-up office BP is 138/88 mm Hg. You also provide him with patient education on lifestyle adjustments to reduce his sodium intake, weight and waist circumference. The DASH diet is not recommended for this patient because of its high potassium content.

**Contributors:** All of the authors listed have contributed substantially to the conception and design of this article, have helped to revise it and have contributed important intellectual content. All of the authors have approved the final version of the manuscript. The first draft of this manuscript was written by Sheldon Tobe, who is acting as guarantor and is responsible for the integrity of the work as a whole, from inception through to publication.

**Acknowledgement:** This clinical practice review is based on CHEP’s annual clinical practice recommendations consensus conference, which was held at the annual congress of Hypertension Canada, 1 Oct. 2011.

## Table 1

| Study          | Treatment group: proportion of patients with hyperkalemia (%) |
|---------------|-------------------------------------------------------------|
|               | Eplerenone-treatment group | Placebo group |
|               | Overall | Patients with GFR ≤ 60* | Patients with GFR > 60* | Overall | Patients with GFR ≤ 60* | Patients with GFR > 60* |
| EPHESUS28      | 15.6†   | 22.1 | 10.8 | 11.2 | 13.8 | 9.3 |
| EMPHASIS-HF29  | 11.8†   | –   | –   | 7.2  | –   | –   |

GFR = glomerular filtration rate.
*GFR was measured in mL·min⁻¹·1.73 m⁻².
†p < 0.001 versus placebo.

**References**

1. Robitaille C, Dai S, Waters C, Loukine L, Bancej C, Quach S, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. *CMAJ* 2012;184(1):e49–e56.
2. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. *Am J Med* 2011;124(9):827–833.
3. Wilkins K, Campbell NR, Joffres MR, McAlister FA, Nichol M, Quach S, et al. Blood pressure in Canadian adults. *Health Rep* 2010;21(1):37–46.
4. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR; CHEP Outcomes Research Task Force. The impact of the Canadian Hypertension Education Programme in its first decade. *Eur Heart J* 2009;30(12):1434–1439.
5. Campbell NRC, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, et al.; Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. *Hypertension* 2009;53(2):128–134.
6. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Eke- kowitz MD, et al. The future burden of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123(8):933–944.

7. Arthur HM, Suskin N, Bayley M, Fortin M, Howlett J, Heckman G, et al. The Canadian Heart Health Strategy and Action Plan: cardiac rehabilitation as an exemplar of chronic disease management. Can J Cardiol 2010;26(1):37–41.

8. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217–223.

9. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287(8):1003–1010.

10. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291(11):1342–1349.

11. Warren RE, Marshall T, Padfield PL, Chrubasik S. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract 2010;60(S78):675–680.

12. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011;342:d286.

13. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al.; Canadian Hypertension Education Program. The Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011;27(4):415–433.

14. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139(4):244–252.

15. Klahr S. Primary and secondary results of the Modification of Diet in Renal Disease study. Miner Electrolyte Metab 1996;22(1–3):138–142.

16. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 2005;142(5):342–351.

17. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Huniscker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123(10):754–762.

18. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al.; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421–2431.

19. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003;14(7 Suppl 2):S154–S165.

20. Appel LJ, Wright JT Jr, Greene T, Agodoa L, Astor BC, Bakris GL, et al.; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363(10):918–929.

21. Ruggenenti P, Perina A, Loriga G, Ganeva M, Ene-Iordache B, Turuturo M, et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939–946.

22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–1187.

23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 7: stratification of risk for progression of kidney disease and development of cardiovascular disease. Am J Kidney Dis 2002;39(2 Suppl 1):S170–S212.

24. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE Clinical Guideline 73. London (UK): Royal College of Physicians; 2008.

25. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–1762.

26. McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Huber E, et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011;27(3):319–338.

27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709–717.

28. Pitt B, Bakris G, Ruijope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118(16):1643–1650.

29. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Wedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11–21.

30. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS investigators. Mol Cell Endocrinol 2004;217(1–2):53–58.

31. Sacks FM, Silverstone WM, Appel LJ, Bray GA, Harsha D, et al.; DASH-Sodium Collaborative Research Group. Effects of blood pressure reduction of dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344(1):3–10.

Published: 16 October 2012

Citation: Tobe SW, Poirier L, Tremblay G, Lindsay P, Reid D, Campbell NRC; Canadian Hypertension Education Program. Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program. Open Med 2012;6(4):e127–e133.

Copyright: Open Medicine applies the Creative Commons Attribution Share Alike License, which means that anyone is able to freely copy, download, reprint, reuse, distribute, display or perform this work and that authors retain copyright of their work. Any derivative use of this work must be distributed only under a license identical to this one and must be attributed to the authors. Any of these conditions can be waived with permission from the copyright holder. These conditions do not negate or supersede Fair Use laws in any country. For more information, please see http://creativecommons.org/licenses/by-sa/2.5/ca/.